FDA Relaxes Oversight of Blood Pressure Wearables, Allowing Unvalidated Devices to Market
The FDA has relaxed regulatory oversight of wellness devices, allowing blood pressure monitoring wearables with unvalidated technology to enter the consumer market without rigorous clinical validation. The policy shift permits manufacturers to market devices directly to consumers without demonstrating accuracy through traditional FDA clearance processes. This regulatory change affects how health plans evaluate remote patient monitoring tools and member-generated health data. The move raises questions about the clinical reliability of biometric data that may be used in care management programs or value-based care arrangements.
Medicaid MCOs relying on remote patient monitoring and member-generated biometric data for chronic disease management must now assess the clinical validity of commercially available devices that may not meet traditional FDA accuracy standards.
Managed Care
You might also like